Morgan Stanley’s Generation Bio GBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-161,378
| Closed | -$917K | – | 8368 |
|
|
2025
Q4 | $917K | Sell |
161,378
-2,892
| -2% | -$16.3K | ﹤0.01% | 5229 |
|
|
2025
Q3 | $1.01M | Buy |
164,270
+72,987
| +80% | +$378K | ﹤0.01% | 5177 |
|
|
2025
Q2 | $292K | Buy |
91,283
+3,389
| +4% | +$13.1K | ﹤0.01% | 5697 |
|
|
2025
Q1 | $356K | Sell |
87,894
-6,089
| -6% | -$42.8K | ﹤0.01% | 5487 |
|
|
2024
Q4 | $996K | Sell |
93,983
-5,984
| -6% | -$107K | ﹤0.01% | 5093 |
|
|
2024
Q3 | $2.47M | Buy |
99,967
+6,327
| +7% | +$167K | ﹤0.01% | 4497 |
|
|
2024
Q2 | $2.64M | Sell |
93,640
-538
| -0.6% | -$17.5K | ﹤0.01% | 4373 |
|
|
2024
Q1 | $3.83M | Sell |
94,178
-118,635
| -56% | -$2.79M | ﹤0.01% | 4125 |
|
|
2023
Q4 | $3.51M | Buy |
212,813
+162,516
| +323% | +$2.83M | ﹤0.01% | 4601 |
|
|
2023
Q3 | $1.91M | Sell |
50,297
-2,125
| -4% | -$101K | ﹤0.01% | 4419 |
|
|
2023
Q2 | $2.88M | Buy |
52,422
+1,043
| +2% | +$47.9K | ﹤0.01% | 4180 |
|
|
2023
Q1 | $2.21M | Buy |
51,379
+2,181
| +4% | +$105K | ﹤0.01% | 4398 |
|
|
2022
Q4 | $1.93M | Buy |
49,198
+510
| +1% | +$26.8K | ﹤0.01% | 4494 |
|
|
2022
Q3 | $2.58M | Buy |
48,688
+28,306
| +139% | +$1.77M | ﹤0.01% | 4254 |
|
|
2022
Q2 | $1.34M | Sell |
20,382
-953
| -4% | -$62.3K | ﹤0.01% | 4823 |
|
|
2022
Q1 | $1.57M | Sell |
21,335
-3,080
| -13% | -$178K | ﹤0.01% | 4689 |
|
|
2021
Q4 | $1.73M | Buy |
24,415
+735
| +3% | +$128K | ﹤0.01% | 4683 |
|
|
2021
Q3 | $5.94M | Sell |
23,680
-1,751
| -7% | -$419K | ﹤0.01% | 3491 |
|
|
2021
Q2 | $6.84M | Buy |
25,431
+25,368
| +40,267% | +$7.59M | ﹤0.01% | 3435 |
|
|
2021
Q1 | $18K | Sell |
63
-844
| -93% | -$270K | ﹤0.01% | 6752 |
|
|
2020
Q4 | $257K | Buy |
907
+715
| +372% | +$229K | ﹤0.01% | 5462 |
|
|
2020
Q3 | $59K | Buy |
+192
| New | +$45.9K | ﹤0.01% | 5663 |
|
Other funds holding GBIO
Morgan Stanley's GBIO Position: Q1 2026 in Review
Morgan Stanley sold out of Generation Bio (GBIO) in Q1 2026, closing a stake of 161,378 shares — an estimated $917K sold.
Morgan Stanley first reported a position in GBIO in Q3 2020 and held it in 22 quarters. The position peaked at $6.84M in Q2 2021. 2 funds tracked by Wall St. Rank hold GBIO as of Q1 2026.
- Morgan Stanley reported no remaining Generation Bio position as of Q1 2026 after selling out during the quarter.
- Morgan Stanley sold 161,378 Generation Bio shares in Q1 2026, an estimated $917K.
- Morgan Stanley first reported a position in Generation Bio in Q3 2020 and held it in 22 quarters.
- Morgan Stanley's Generation Bio position peaked at $6.84M in Q2 2021.
- 2 funds tracked by Wall St. Rank held Generation Bio as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.